Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: AzurRx BioPharma Inc. AZRX

MissionIRNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Aims to Identify Best Delivery Method for Lead Drug Candidate

Posted on December 22, 2020 by MissionIR

AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, recently submitted a protocol amendment request to the U.S. Food and Drug Administration (“FDA”). Approval of the amendment will allow AzurRx … Continue reading →

Posted in AzurRx BioPharma Inc. AZRX | Leave a comment

MissionIRNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Advancing MS1819 in Fight to Improve Treatment of EPI in CF, CP Patients

Posted on December 11, 2020 by MissionIR

AzurRx BioPharma (NASDAQ: AZRX) is focused on the development of its lead drug candidate, MS1819, for exocrine pancreatic insufficiency (“EPI”) in patients suffering from cystic fibrosis (“CF”) and chronic pancreatitis (“CP”). While CF is a relatively rare genetic disease, innovative … Continue reading →

Posted in AzurRx BioPharma Inc. AZRX | Leave a comment

MissionIRNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Advancement of MS1819 Combination Therapy Trial in Turkey

Posted on November 30, 2020 by MissionIR

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that the first two patients have been dosed in Turkey for its Phase 2 trial. The trial evaluates its investigational drug, MS1819, … Continue reading →

Posted in AzurRx BioPharma Inc. AZRX | Leave a comment

AzurRx BioPharma Inc. (NASDAQ: AZRX) Planning to Test Immediate Release MS1819 Capsules in Cystic Fibrosis Study

Posted on November 25, 2020 by MissionIR

The company plans to add another study arm to its ongoing Phase 2b OPTION 2 clinical study which currently tests delayed release capsules If it receives FDA approval, AzurRx would be able to identify the optimal delivery method for its … Continue reading →

Posted in AzurRx BioPharma Inc. AZRX | Leave a comment

MissionIRNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Featured in Stock2Me Podcast

Posted on November 24, 2020 by MissionIR

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, was featured in InvestorBrandNetwork’s (“IBN”) latest episode of its Stock2Me Podcast. Stock2Me Podcasts feature a fascinating array of companies and individuals, many of whom … Continue reading →

Posted in AzurRx BioPharma Inc. AZRX | Leave a comment

MissionIRNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Featured in Simply Wall St Article

Posted on November 20, 2020 by MissionIR

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, was featured in a recent Simply Wall St article. The piece, titled “Is AzurRx BioPharma (NASDAQ:AZRX) In A Good Position To Invest In Growth?,” … Continue reading →

Posted in AzurRx BioPharma Inc. AZRX | Leave a comment

AzurRx BioPharma Inc. (NASDAQ: AZRX) Making Strides with MS1819 Clinical Trials for Cystic Fibrosis-Associated Pancreatic Insufficiency

Posted on November 17, 2020 by MissionIR

Globally it is estimated that 70,000 people suffer from CF, with half the population in the United States The global CF therapeutics market size was valued at $4.62 billion in 2018 and is expected to reach an estimated $9.3 billion … Continue reading →

Posted in AzurRx BioPharma Inc. AZRX | Leave a comment

MissionIRNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Requests Protocol Amendment to Phase 2b Study to Add Study Arm

Posted on November 17, 2020 by MissionIR

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of nonsystemic, recombinant therapies for gastrointestinal diseases, will be submitting a protocol amendment request to the U.S. Food and Drug Administration (“FDA”) for its Phase 2b OPTION 2 trial of MS1819 for the … Continue reading →

Posted in AzurRx BioPharma Inc. AZRX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Enters LOI with Asymchem for MS1819 Development, Production

Posted on November 10, 2020 by MissionIR

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced its entry into a binding letter of intent (“LOI”) with Asymchem, a leading global contract development and manufacturing service (“CDMO”) provider, for … Continue reading →

Posted in AzurRx BioPharma Inc. AZRX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Secures $6.9M in Private Placement

Posted on November 2, 2020 by MissionIR

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, earlier this year announced the closing of a private placement financing (the “offering”). According to the update, AzurRx secured approximately $6.9 million in gross … Continue reading →

Posted in AzurRx BioPharma Inc. AZRX, MissionIRNewsBreaks | Leave a comment